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Abstract
Familial British dementia (FBD) and familial Danish dementia (FDD) are caused by mutations in 
the BRI2 gene. These diseases are characterized clinically by progressive dementia and ataxia and 
neuropathologically by amyloid deposits and neurofibrillary tangles. Herein, we investigate BRI2 
protein accumulation in FBD, FDD, Alzheimer disease and Gerstmann-Sträussler-Scheinker 
disease. In FBD and FDD, we observed reduced processing of the mutant BRI2 pro-protein, which 
was found accumulating intracellularly in the Golgi of neurons and glial cells. In addition, we 
observed an accumulation of a mature form of BRI2 protein in dystrophic neurites, surrounding 
amyloid cores. Accumulation of BRI2 was also observed in dystrophic neurites of Alzheimer 
disease and Gerstmann-Sträussler-Scheinker disease cases. Although it remains to be determined 
whether intracellular accumulation of BRI2 may lead to cell damage in these degenerative 
diseases, our study provides new insights into the role of mutant BRI2 in the pathogenesis of FBD 
and FDD and implicates BRI2 as a potential indicator of neuritic damage in diseases characterized 
by cerebral amyloid deposition.
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1. Introduction
Mutations in the BRI2 gene are associated with familial British dementia (FBD) and familial 
Danish dementia (FDD; Vidal et al., 1999, 2000). These diseases are characterized clinically 
by a progressive dementia and ataxia and neuropathologically by amyloid deposition and tau 
aggregation (Holton et al., 2001, 2002; Vidal et al., 1999, 2000). The BRI2 protein contains 
266 amino acids (aa) and belongs to a family of integral type II single trans-membrane 
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domain proteins (Deleersnijder et al., 1996; Vidal et al., 1999, 2001). As other proteins of 
the regulated pathway, BRI2 is produced as a pro-protein with a pro-peptide sequence that is 
cleaved by pro-protein convertases (PCs). Cleavage by PCs between the BRI2 ectodomain 
(residue Arg243 and Glu244, KGIQKR↓EAS; Choi et al., 2004; Kim et al., 1999, 2002) 
produces a mature protein (mature BRI2 protein or m-BRI2) and a 23 aa C-terminal pro-
peptide (Bri2-23; Fig. 1). Ectodomain cleavage also releases the ABri and ADan amyloids 
(last 34 aa C-terminal peptides) from the mutant BRI2 polypeptides (277 aa). These peptides 
are transported via regulated secretory pathway through axons for secretion (Choi et al., 
2004). Processing of BRI2 is complex, involving several proteases in addition to PCs. The 
BRI2 pro-protein and m-BRI2 protein may also be cleaved by the disintegrin and 
metalloproteinase domain-containing protein 10 (ADAM10), releasing a BRICHOS domain 
(Sanchez-Pulido et al., 2002), and an N-terminal fragment (NTF). The NTF is also the 
subject of additional proteolysis by signal peptide peptidase-like 2 (SPPL2; Fluhrer et al., 
2012), releasing an intracellular domain and a BRI2 C-peptide (Fig. 1; Choi et al., 2004; 
Garringer et al., 2010, 2013; Martin et al., 2008, 2009). The BRICHOS domain consists of ~ 
100 aa and is found in several different type II membrane proteins, including BRI2, 
Chondromodulin-I, CA11, and surfactant protein C (Sanchez-Pulido et al., 2002; Willander 
et al., 2011). The domain has 2 conserved cysteine residues that form a disulfide bridge. 
Disulfide-bonded loops within pro-proteins and neuropeptides have been shown to be 
important for sorting of peptides from the trans-Golgi network to regulated secretory 
pathway (Glombik et al.,1999; Krömer et al.,1998). BRI2 has a single N-linked 
glycosylation site (Asp170) inside the BRICHOS domain that has been shown in vitro to be 
important for BRI2 trafficking to the cell surface and its steady state levels at the plasma 
membrane (Tsachaki et al., 2011).
The mutant BRI2 pro-protein is not efficiently processed by PCs to generate m-BRI2 and has 
been found to accumulate intracellularly in a transgenic mouse model of FDD (Tg-FDD; 
Garringer et al., 2013; Tamayev et al., 2010a,b; Vidal et al., 2009). In addition, dystrophic 
neurites (DNs) consisting of large globular processes surrounding ADan amyloid cores in 
Tg-FDD mice also show the presence of BRI2, in agreement with previous 
immunohistochemical studies that have shown BRI2 deposits in DNs of Alzheimer disease 
(AD), around ischemic lesions, in torpedoes and grumose changes in the cerebellum, as well 
as in Lewy neurites, ballooned neurons, and neurons undergoing hypoxia (Akiyama et al., 
2004; Baron and Pytel, 2016; Del Campo et al., 2014). DNs in Tg-FDD mice are labeled by 
antibodies (abs) against the N-terminus of BRI2 but not by abs against the C-terminus of the 
mutant BRI2 protein (Garringer et al., 2013), suggesting that they contain m-BRI2 rather 
than immature BRI2 protein.
Herein, we studied BRI2 processing and intracellular accumulation of BRI2 in FBD, FDD, 
AD, and Gerstmann-Sträussler-Scheinker disease (GSS), diseases characterized 
neuropathologically by amyloid deposits and tau accumulation. As controls, intracellular 
accumulation of BRI2 was assessed in familial multiple system tauopathy with presenile 
dementia (MSTD) and normal individuals. Our studies show that the ectodomain processing 
of the mutant form of BRI2 by PCs is compromised in FBD and FDD, leading to the 
intracellular accumulation of immature BRI2 in the Golgi compartment of neurons and glial 
cells. In addition, we observe the accumulation of m-BRI2 in DNs in association with the 
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presence of amyloid cores in FBD, FDD, AD, and GSS. Accumulation of m-BRI2 was not 
seen in association with neurofibrillary tangles (NFTs) of FBD, FDD, AD, and GSS, as well 
as in tau deposits in MSTD. Although it is not known if intracellular accumulation of BRI2 
ultimately results in cell damage, these studies provide new insights into the mechanisms of 
neurodegeneration in brain diseases characterized by amyloid deposition and tau 
aggregation.
2. Methods
2.1. Generation of expression constructs
The cDNA encoding human wild-type BRI2, and the FBD and FDD mutants forms of BRI2 
with the addition of a Kozak sequence and an N-terminal Myc epitope tag were PCR 
amplified, gel purified, and sub-cloned into pcDNA 3.1 directional TOPO vector 
(Invitrogen). Plasmids were transformed into DH5alpha cells (Invitrogen), and positive 
colonies were screened by restriction enzyme analysis and direct DNA sequencing. To 
introduce an Asp to Ala change at aa 170, site-directed mutagenesis (Agilent Technologies) 
was done according to the manufacturer’s protocol using primers forward (5′-CTA TGT 
GAT CCC TCT GGC CAC TTC CAT TGT TAT GC-3′) and reverse (5′-GCA TAA CAA 
TGG AAG TGG CCA GAG GGA TCA CAT AG-3′).
2.2. Cell culture and transfection
Mouse neuroblastoma N2a cells (ATCC) were maintained in 50% Dulbecco’s modified 
Eagle’s medium (Lonza) supplemented with 5% fetal bovine serum and 100 units/ml 
penicillin/streptomycin/amphotericin (Pen/Strep/Amp). Hek293 cells (ATCC) were 
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine 
serum, 100 units/ml Pen/Strep/Amp, and 2-mM L-Glutamine. N2a cells were transiently 
transfected using LipofectAMINE PLUS (Invitrogen) for 5–6 hours with 2 µg of supercoiled 
plasmid DNA and analyzed after 48 hours. To generate stable cell lines, Hek293 and N2a 
cells were transfected using Fugene 6 (Roche). Twenty-four hours following transfection, 
the media were replaced with selection media, growth media supplemented with 750-ug/mL 
G418 (Mediatech). Selected expressing clones were used for further analysis.
2.3. Antibodies
For immunohistochemical and biochemical studies, we use antibodies against the ABri and 
ADan amyloid peptides which also recognize the C-terminus of the immature forms of 
mutant BRI2 (Vidal et al., 2009). We also used abs against the N-terminus of BRI2: ab14307 
(Abcam) and 11–26 (Akiyama et al., 2004). Abs against c-Myc (Santa Cruz) and against 
beta-actin (AC-15, Sigma) were also used. Secondary abs used for Western blot ECL 
detection were donkey anti-rabbit IgG, HRP (NA934, GE Healthcare), anti-mouse IgG, HRP 
(NA931, GE Healthcare), and anti-chicken IgY, HRP (A9046, Sigma-Aldrich). For confocal 
studies, BRI2 proteins were detected with anti-c-Myc and secondary Alexa Fluor 594 goat 
anti-mouse (Invitrogen). Calnexin was detected with anti-Calnexin (Abcam) and secondary 
Alexa Fluor 488 goat anti-rabbit (Invitrogen). GM130 was detected with anti-GM130 
(Abcam) and secondary Alexa Fluor 488 goat anti-rabbit (Invitrogen).
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2.4. Sample preparation and Western blot
Transfected cells were washed in phosphate-buffered saline (PBS) at 4 °C and lysed in tris-
buffered saline containing 1% sodium dodecyl sulfate and protease inhibitors (Complete, 
Roche). Post-nuclear supernatants were prepared by homogenizing the mouse neocortex in 3 
volumes of cold Hepes-sucrose buffer (20-mM Hepes, 1-mM EDTA, 1-mM EGTA, 0.25-M 
sucrose, all from Sigma) containing protease inhibitors (Complete, 1-mM pepstatin, 100-
mM TLCK- HCl, 200-mM TPCK, and 1-mM leupeptin; all from Roche). The homogenates 
were centrifuged at 1000 g for 10 minutes and the postnuclear supernatants retained for 
western analysis. For PNGase treatment, protein samples were treated with PNGase (New 
England BioLab) according to the manufacturer’s instructions. Protein concentrations were 
determined with the BCA Protein Assay Kit (Pierce). Forty micrograms of protein were 
used for Western blot analysis. Proteins were separated on Mini-Protean TGX Precast gels 
(Bio-Rad), run under denaturing conditions and electrotransferred to Immobilon PVDF 
membrane (Millipore). Membranes were blocked with 0.01% milk in PBS (10-mM 
phosphate, pH 7.4, 150-mM NaCl) with 0.05% Tween-20 (PBS-T, all from Sigma) using the 
SNAP ID protein detection system (Millipore) then incubated 2 hours or overnight with the 
primary ab. Following washes with PBS-T buffer, membranes were incubated 1 hour with 
the appropriate HRP-conjugated secondary ab and visualized using the Pierce ECL Pico kit 
(Pierce). To ensure equal protein loading, blots were probed with anti-β-actin. Blots were 
scanned and quantified using Image J software from NIH. Statistical analysis was done 
using GraphPad Prism (GraphPad Software).
2.5. Histology and immunohistochemistry
Mice were anesthetized and perfusion fixed with 4% paraformaldehyde in 0.1-M phosphate 
buffer, pH 7.2 (Sigma-Aldrich). Brains were removed, embedded in paraffin. Sections (8-µm 
thick) were cut and mounted on poly-l-lysine-coated slides and stained with hematoxylin 
and eosin. Immunohistochemical staining was performed as previously described (Garringer 
et al., 2013). Immunohistochemical studies were also carried out in paraffin sections from 
cerebral cortex, hippocampus, and cerebellum from individuals affected by sporadic AD, 
familial AD (FAD; PSEN1-V261I mutation; Miravalle et al., 2005), GSS (PRNP-F198S 
mutation; Ghetti et al., 1989, 1995), FBD, and FDD (Vidal et al., 1999, 2000), MSTD 
(MAPT IVS10+3 G>A; Spillantini et al., 1998), and age-matched controls.
2.6. Confocal microscopy
Glass 4-chamber slides (Nunc) were coated with 0.1-mg/ml Poly-D-Lysine (Invitrogen) 
diluted in sterile water. The surface of each well was covered with the poly-D-lysine solution 
for 5 minutes at room temperature, then rinsed with sterile water, and allowed to air dry 2 
hours before the use. Stably transfected Hek293 cells were plated 2000 cells per well and 
cultured in growth media 24 hours. The slides were then fixed for 15 minutes at 37 °C in 4% 
paraformaldehyde, blocked with 2% BSA (Sigma) and 1% Triton (Acros Organics) in PBS 
overnight at 4 °C. The slides were incubated with primary abs and with the appropriate 
fluorescently labeled secondary ab for 60 minutes at 37 °C in the dark. BRI2 proteins were 
detected with anti-c-Myc and secondary Alexa Fluor 594 goat anti-mouse. Endoplasmic 
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reticulum (ER) was detected with anti-Calnexin, secondary Alexa Fluor 488 goat anti-rabbit. 
The Golgi apparatus was detected with GM130, secondary Alexa Fluor 488 goat anti-rabbit.
3. Results
3.1. BRI2 protein, processing, and post-translational modifications
Cleavage of BRI2 pro-protein by PCs to generate m-BRI2 is more efficient for the wild-type 
BRI2 protein than mutant BRI2. Further processing of m-BRI2 by ADAM10 releases a large 
part of the ectodomain of BRI2 containing the BRICHOS domain and leaves a membrane-
associated NTF of ~ 17 kDa (Fig. 2A). Deglycosylation using PNGaseF of protein extracts 
from transfected cell lines affects the mobility of full-length BRI2 and m-BRI2 proteins, but 
not that of the NTF (Fig. 2B), suggesting that ADAM10 cleavage in BRI2 occurs N-terminal 
from the glycosylation site at Asn 170. Treatment with PNGaseF also affects the mobility of 
the C-terminal fragment, which contains the pro-peptide sequence and the glycosylated 
BRICHOS domain, suggesting that processing by ADAM10 can occur independently from 
PC cleavage of BRI2 (Fig. 2C). The remaining NTF attached to the cell membrane may 
undergo RIP by SPPL2a or SPPL2b, releasing an intracellular domain and a C-terminal 
peptide fragment (BRI2 C-peptide; Fig. 1).
3.2. Intracellular BRI2 accumulation and role of glycosylation
Western blot analysis shows that ectodomain processing by PCs of the FBD and FDD 
mutant forms of BRI2 is compromised, leading to an intracellular accumulation of mutant 
BRI2 pro-protein. Confocal microscopic analysis of stable transfected HEK293 cells using 
abs against a c-Myc tag on the N-terminus of the BRI2 pro-protein shows that the protein 
localizes to the cell membrane, with the wild-type protein also colocalizing with the ER 
marker calnexin (Fig. 3). Analysis of cells expressing the FBD and FDD mutant forms of the 
BRI2 protein by confocal microscopy shows that the mutant proteins accumulate and 
colocalize with the Golgi marker GM130 (Fig. 3). Analysis of brain protein extracts from 
Tg-FDD mice suggests that the glycosylated mutant form of the BRI2 protein accumulates 
intracellularly in vivo, whereas the treatment with PNGaseF modifies the mobility of the 
FDD-mutant BRI2 pro-protein and m-BRI2 protein (Fig. 4A). Since synthesis of complex 
type N-linked oligosaccharide chains begins with the cotranslational addition of core 
mannose–rich oligosaccharide chains to the protein, which are then trimmed and new sugars 
are added as the protein is processed through the Golgi (Kornfeld and Kornfeld, 1985), we 
determined whether protein accumulation had any effect on the glycosylation of BRI2. 
Knock-out of the glycosylation site (Asn170Ala mutation) in wild-type and mutant BRI2 led 
to an increase in the mobility of BRI2 pro-protein and m-BRI2 but did not change the 
mobility of the NTF (Fig. 4B). Lack of glycosylation did not seem to modify the processing 
of the BRI2 protein. Confocal analysis of stable-transfected Hek293 cells with the 
Asn170Ala mutated BRI2 protein showed colocalization of the protein with the ER marker 
calnexin, but a significant amount of the immunoreactivity was also seen to colocalize with 
the Golgi marker GM130 (Fig. 5). Analysis of the FBD and FDD mutant forms of BRI2 with 
the Asn170Ala change did not show a significant change in the localization of the mutant 
proteins (Fig. 5).
Garringer et al. Page 5
Neurobiol Aging. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3.3. Accumulation of BRI2 in glial cell bodies in FBD and FDD
Immunohistochemical studies using abs against the N-terminus of BRI2 revealed the 
presence of intracellular immunopositive perinuclear accumulation of ubiquitinated (not 
shown) BRI2 in neurons and glial cells of Tg-FDD mice (Fig. 6A–C). Abs that recognize the 
C-terminus of the mutant precursor protein and the ADan amyloid peptide revealed also the 
presence of intracellular protein accumulation in addition to amyloid deposits (Fig. 6D and 
E). The finding of immunoreactivities for both N- and C-terminal epitopes suggests the 
accumulation of full-length mutant BRI2 pro-protein. Immunohistochemical studies using 
the C-terminal ab revealed the presence of intracellular perinuclear accumulation of BRI2 in 
a patient with FDD (Fig. 6F–H, black arrows) and a patient with FBD (Fig. 6I and J, black 
arrows) in addition to amyloid deposits.
3.4. Accumulation of BRI2 in DNs in AD and GSS
In FBD, FDD, and Tg-FDD mice, analysis of brain sections shows clusters of swollen 
neurites surrounding amyloid cores that are recognized by abs specific for the N-terminus of 
BRI2 but not by the C-terminal abs (Garringer et al., 2013; Vidal et al., 2009). Since these 
profiles appeared to be associated with amyloid cores, we analyzed sections from the 
cerebral cortex, hippocampus, and cerebellum from the cases of sporadic AD (Fig. 7A–C 
and E), FAD (Fig. 7D), and GSS (Fig. 7F–I), which are characterized by extracellular 
amyloid deposition and intracellular NFTs. In all cases, we detected N-terminal BRI2 
immunoreactive DNs surrounding amyloid cores. Staining was not observed after omitting 
the first ab, whereas a similar immunoreactive profile was observed using 2 different 
primary abs against the N-terminus of BRI2 (Fig. 7E). In the cerebellum, in addition to the 
swollen neurites around amyloid cores, the N-terminal BRI2 ab labeled cell bodies, 
dendrites, and axons of Purkinje cells (Fig. 7D and I). Immunostaining of tissue from normal 
controls and a case of MSTD showed the previously described pattern of normal cellular 
staining using N-terminal BRI2 abs (Akiyama et al., 2004).
4. Discussion
Cleavage by PCs within the BRI2 ectodomain is the main proteolytic event that releases the 
mutant peptides found deposited as ABri amyloid in FBD patients and ADan amyloid in 
FDD patients (Vidal et al., 1999, 2000). The mutant precursor proteins are inefficiently 
cleaved by PCs, leading to the intracellular accumulation of immature mutant BRI2 pro-
protein in neurons and glial cells in patients with FBD, FDD, and a transgenic mouse model 
of FDD, but the significance of this finding for our understanding of the pathologic process 
associated with FBD and FDD is not known. The accumulation of immature mutant BRI2 
pro-protein may be caused by the mutant sequences interfering with the correct folding of 
BRI2 and the enzymatic activity of PCs. In addition, they may also disrupt information 
required for efficient Golgi exit. The molecular mechanism responsible for the abnormal 
processing of mutant BRI2 may involve the BRICHOS domains, which seems to have 
intramolecular chaperone-like function protecting and avoiding pro-peptide aggregation 
(Johansson et al., 2006, 2009; Peng et al., 2010). Several interstitial lung diseases have been 
linked to mutations in the SP-C gene, SFTPC, with the great majority of these mutations 
found within the BRICHOS domain of the pro-peptide where mutations are believed to 
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affect pro-peptide folding and conformation. Mutagenesis of one or both of the cysteines in 
the BRICHOS domain of SP-C results in misfolding of the pro-peptide and mistargeting of 
the unprocessed mutant protein (Kabore et al., 2001). In addition, in vitro experiments have 
shown that the BRICHOS domain can bind amyloidogenic peptides and affect fibril 
formation (Willander et al., 2011, 2012). Thus, in FBD and FDD, the BRICHOS domain 
may regulate negatively the enzymatic processing of the pro-protein by interacting with the 
amyloidogenic sequences of ABri and ADan in the mutant precursor proteins. The 
interaction between the BRICHOS domain and the amyloidogenic sequences may alter the 
accessibility of PCs to the cleavage site, resulting in the abnormal processing of the 
immature proteins and the targeting of the unprocessed precursor to the Golgi. Since the 
glycosylation site (aa 170) is present in the BRICHOS domain of BRI2, changes in the 
folding of BRI2 could affect glycosylation of BRI2 and eventually the processing and the 
trafficking of BRI2. Vice versa, some glycosylation sites seem to be crucial for protein 
folding but their removal from folded proteins often does not affect the protein fold and 
function (Shental-Bechor and Levy, 2008). We observed that mutagenesis of Asn 170 had no 
remarkable effect on wild-type and mutant BRI2 processing by PCs or ADAM10 but leads to 
the intracellular accumulation of BRI2 as previously reported (Tsachaki et al., 2011). Wild-
type BRI2 with the N170A substitution accumulated in a Golgi compartment, similarly to 
the FBD and FDD mutant forms of BRI2, suggesting that glycosylation plays an important 
role in protein trafficking of BRI2. These data highlight the importance of considering the 
intracellular accumulation of immature mutant BRI2 pro-protein in the pathobiology of FBD 
and FDD. In AD, numerous lines of evidence suggest that in addition to Aβ, some of the 
neurotoxicity associated with AD may be due to the accumulation of C-terminal proteolytic 
fragments of the amyloid β precursor protein (AβPP), which have been found in patients 
with the disease and in animal models (Chang and Suh, 2005; Vidal et al., 2012).
In FBD and FDD, we have also observed the presence of large and rounded processes, 
strongly immunolabeled by abs against the N-terminus of BRI2 (but not the C-terminus) in 
association with amyloid cores, although some of these processes may be also observed in 
the absence of amyloid cores. The finding of m-BRI2 in DNs, which symbolize neuritic 
damage (Masliah et al., 1993), suggest an accumulation of m-BRI2 protein that is different 
from the accumulation of the immature protein observed in the Golgi in FBD and FDD. The 
N-terminal abs also showed similar accumulation of m-BRI2 in DNs in association with Aβ 
in AD and APrP in GSS. No immunolabeling was observed in NFTs of AD and GSS, nor in 
tau deposits of MSTD. Our results are in agreement with those by Akiyama (Akiyama et al., 
2004), who reported positive BRI2 immunostaining in globular DNs in senile plaques in AD 
using an N-terminal ab. As in our study, NFT of AD cases were negative for BRI2. Similar 
immunohistochemical data in AD have been recently reported, although the authors suggest 
accumulation of an immature form of BRI2 based on Western blot data (Del Campo et al., 
2014). Accumulation of m-BRI2 in DNs may occur as a consequence of a reduction of tau 
binding to microtubules and resulting impairment in transport of m-BRI2 (Garringer et al., 
2013), leading to m-BRI2 accumulation in DNs. They are immunoreactive for a wide variety 
of synaptic, cytoskeletal, and growth-related proteins, including AβPP (Blanchard et al., 
2003). A potential molecular mechanism by which abnormal accumulation of m-BRI2 in 
DNs may be deleterious to the cell could involve the role of BRI2 in the processing of AβPP 
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(Fotinopoulou et al., 2005; Matsuda et al., 2005). Mature BRI2 binds the C-terminus of 
AβPP, masking the cleavage sites of β- and α-secretase and the γ-secretase docking site on 
C99. Interestingly, this interaction occurs only between m-BRI2 and mature AβPP (m-
AβPP), downstream of the trans-Golgi complex (Matsuda et al., 2008). Indeed, maturation 
of BRI2 into m-BRI2 and transport of m-BRI2 along the secretory pathway are required to 
generate a functional AβPP processing inhibitor (Matsuda et al., 2011a). Thus, abnormal 
accumulation and subcellular localization of m-BRI2 could reduce the interaction between 
m-BRI2 and m-AβPP in vivo leading to an increase in the production of Aβ peptides 
(Matsuda et al., 2009, 2011b; Tamayev and D’Adamio, 2012; Tamayev et al., 2011). The 
finding of Aβ codeposited with ADan in the brain of patients with FDD seems to support 
this hypothesis (Vidal et al., 2000). In FDD, parenchymal and vascular ADan deposition 
exceeds that of Aβ, with some deposits being composed of Aβ or ADan alone, and in a 
considerable number of cases showing colocalization of both peptides (Holton et al., 2002). 
Importantly, the finding of m-BRI2 accumulation in DNs in GSS suggests that m-BRI2 may 
be involved in a similar cellular degenerative pathway in these diseases, marked by amyloid 
accumulation and tau fibrillar deposition and neurodegeneration.
In summary, we showed that the extended C-terminus of BRI2 originated by mutations in the 
BRI2 gene in FBD and FDD reduced the processing of the protein leading to the intracellular 
accumulation of the immature protein in the Golgi. Future studies will determine the 
molecular mechanism(s) involved in the intracellular accumulation of mutant BRI2 and its 
potential role in the pathogenesis of FBD and FDD. We also observed a second type of BRI2 
accumulation in the form of DNs associated with 4 different cerebral amyloidogenic 
peptides (ABri, ADan, Aβ, and APrP), likely containing m-BRI2. The study of m-BRI2 
protein accumulation in DNs may provide insights into the molecular mechanism(s) 
underlying neuronal dysfunction in association with cerebral amyloidosis.
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Fig. 1. 
Proteolytic processing of BRI2. Scheme showing the processing of the type-II single trans-
membrane (TM) domain BRI2 protein. Processing of the pro-protein (or immature protein, 
im-BRI2) by pro-protein convertases (PCs) generates a 23 amino acid (aa) peptide (Bri2-23) 
and a mature form of BRI2 (m-BRI2). Processing of the FBD and FDD forms of BRI2 by 
PCs releases the 34 aa amyloid peptides (ABri and ADan). Processing by ADAM10 in the 
ectodomain of BRI2 releases the BRICHOS domain (~ 100 aa) and the N-terminal fragment 
(NTF). The NTF is also the subject of additional proteolysis by SPPL2, releasing an 
intracellular domain (ICD) and a C-terminal peptide fragment (BRI2 C-peptide). Disulfide-
bonded loops in the BRICHOS domain and in the carboxy-terminus of BRI2 (aa 5 and 22 of 
the Bri2-23 peptide) are indicated as well as the single N-glycosylation site (Glyc) at 
position 170. The figure shows the location of the epitope recognized by the N-term abs.
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Fig. 2. 
BRI2 proteolytic fragments after the treatment with PNGaseF. (A). Analysis of BRI2 
processing in transfected N2a cells. Expression constructs encoding an N-terminal c-Myc-
tagged wild-type BRI2 and the FDD mutant form of BRI2 (FDD) were transiently 
transfected into N2a cells. Western blot analysis of cell lysates using anti-c-Myc abs shows 
the ectodomain processing of BRI2 generating m-BRI2. Processing of the FDD mutant form 
of BRI2 by PCs is compromised, with accumulation of im-BRI2. The NTF (~ 17 kDa) 
released by ADAM10 processing is indicated. (B). Mobility of BRI2 fragments after the 
treatment with PNGaseF. Western blot analysis of N2a cells using anti-c-Myc abs shows that 
PNGaseF removed the oligosaccharide chains from both the full-length and mature forms of 
BRI2 (shown for the FDD mutant form of BRI2) without affecting the migration of the NTF 
since the glycosylation site is included in the domain released by ADAM10 processing. (C). 
Western blot analysis of N2a cells using the C-terminal ab that recognizes the C-terminus of 
the mutant precursor protein. Treatment with PNGaseF removed the oligosaccharide chains 
from both the full-length im-BRI2 and the C-terminal peptide that is released by ADAM10 
cleavage from the NTF. The C-terminal peptide has the sequence of the BRICHOS domain 
and the pro-peptide, which contains the sequence of the ADan amyloid peptide before 
cleavage by PCs. m-BRI2 could not be detected since PC cleavage removes the C-terminal 
sequence recognized by the ab. Samples were run in triplicates. Representative samples are 
shown.
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Fig. 3. 
Subcellular localization of wild-type and mutant forms of BRI2. Confocal 
immunofluorescence microscopy shows that the BRI2 protein localize to the cell membrane, 
with the wild-type protein also colocalizing with the ER marker calnexin. Analysis of the 
localization of the FBD and FDD mutant precursor proteins shows a different pattern. In 
addition to some degree of ER co-localization, the mutant proteins colocalize with the Golgi 
marker GM130. Confocal immunofluorescence microscopy was performed in Hek293 cells 
stable transfected with wild-type (BRI2), the FDD mutant form of BRI2 (FDD), and the FBD 
mutant form of BRI2 (FBD) using the N-terminal Myc ab (red), an ab against Calnexin 
(green) and an ab against GM130 (green). Nuclei were stained with DAPI (blue). A merge 
of the images is shown on the right panels. Abbreviations: FBD, familial British dementia; 
FDD, familial Danish dementia. (For interpretation of the references to color in this figure 
legend, the reader is referred to the Web version of this article.)
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Fig. 4. 
BRI2-Asn170 and BRI2 processing. (A). Glycosylation of BRI2 in Tg-FDD mice. Treatment 
with PNGaseF of PNS from neocortex of Tg-FDD mice affects the mobility of the mutant 
im-BRI2 and m-BRI2 proteins, demonstrating that the protein is glycosylated in vivo. (B). 
Knock-out of the glycosylation site at position 170 of BRI2. An Asn170Ala change in the 
BRI2 sequence leads to an increase in the mobility of the immature and mature forms of 
BRI2 without altering the migration of the NTF or the overall processing pattern of the 
protein in wild-type and the FBD and FDD mutant forms of BRI2. Analysis was performed 
in Hek293 cells stable transfected with wild-type BRI2 (WT), the FBD mutant form of BRI2 
(FBD), and the FDD mutant form of BRI2 (FDD) using the N-terminal Myc ab. N indicates 
Asn at aa 170; A indicates Ala at aa 170. Samples were run in triplicates. Representative 
samples are shown. Abbreviations: FBD, familial British dementia; FDD, familial Danish 
dementia; NTF, N-terminal fragment; PNS, postnuclear supernatants.
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Fig. 5. 
Subcellular localization of wild-type and mutant forms of BRI2 with an Asn170Ala 
substitution. Confocal analysis shows that the Asn170Ala BRI2 protein still colocalizes with 
the ER marker calnexin, but a significant amount of the immunoreactivity now also 
colocalizes with the Golgi marker GM130. Analysis of the FBD and FDD mutant forms of 
BRI2 with the Asn170Ala change show, in addition to a small degree of ER colocalization, a 
strong colocalization with the Golgi marker GM130 as did the FBD and FDD mutants with 
Asn 170. Confocal immunofluorescence microscopy was performed in Hek293 cells stable 
transfected with wild-type (BRI2), the FDD mutant form of BRI2 (ADanPP), and the FBD 
mutant form of BRI2 (ABriPP) using the N-terminal Myc ab (red), an ab against Calnexin 
(green), and an ab against GM130 (green). Nuclei were stained with DAPI (blue). A merge 
of the images is shown on the right panels. Abbreviations: ER, endoplasmic reticulum; FBD, 
familial British dementia; FDD, familial Danish dementia. (For interpretation of the 
references to color in this figure legend, the reader is referred to the Web version of this 
article.)
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Fig. 6. 
Accumulation of mutant BRI2 in FBD and FDD. Immunohistochemical studies using the 
BRI2-N -terminal ab show intracellular deposits in neurons and glia (A–C) and globular 
DNs (A) in Tg-FDD mice. The ab against the C-terminus of the mutant precursor protein 
reveals only the presence of intracellular perinuclear aggregates in Tg-FDD mice (D, E, 
black arrows). Immunohistochemical studies using abs against the C-terminal sequence that 
recognizes the C-terminus of the mutant precursor protein in a patient with FDD reveal the 
presence of intracellular protein accumulation (F–H, black arrows) in addition to amyloid 
deposits. Immunohistochemical studies using abs that recognize the C-terminus of the 
mutant precursor protein and the ABri amyloid peptide in a patient with FBD show 
intracellular protein accumulation (I, J, black arrows) in addition to amyloid deposits. 
Sections were from the hippocampus (A, E) and neocortex (B–D) of a 21-month old Tg-
FDD mouse, neocortex of an FDD case (F–H), and neocortex of an FBD case (I, J). 
Immunohistochemistry using the N-term BRI2 ab14307 (A–C), the C-term ab against the 
Danish mutant (D–H), and the C-term ab against the British mutant (I, J). Scale bars: A, F, 
50 µm; B–E and G–J are high magnification from 100×. Abbreviations: DNs, dystrophic 
neurites; FBD, familial British dementia; FDD, familial Danish dementia.
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Fig. 7. 
Intracellular accumulation of m-BRI2 in patients with Alzheimer disease and Gerstmann-
Sträussler-Scheinker disease. The BRI2-amino-terminal ab labels globular DNs in sections 
from patients with AD (B, C), FAD (D), and GSS (F, H, I). These profiles are associated 
with amyloid cores (A, G), although some clusters of DNs may also be seen in the absence 
of amyloid deposits. DNs on a section from a patient with AD are also labeled using the 
BRI2-amino-terminal ab 11–26 (E). In the cerebellum, the N-terminal BRI2 ab labeled 
swollen neurites at the periphery of cerebellar amyloid cores, and cell bodies, dendrites, and 
axons of Purkinje cells of AD and GSS cases (D, I). Immunostaining of normal controls and 
a case of MSTD showed normal cellular staining. Arrows indicate the presence of Aβ and 
APrP amyloid cores. Sections were from the hippocampus of a sporadic AD case (A–C, E), 
cerebellum from a FAD case (D), and cerebellum from a GSS case (F–I). Thioflavine S (A, 
G). Immunohistochemistry using the BRI2 N-term ab14307 (B–D, F, H–I) and ab 11–26 (E). 
Scale bars: A, B, D, E, G–I, 50 µm; F, 20 µm; C, 10 µm. Abbreviations: DNs, dystrophic 
neurites; FBD, familial British dementia; FDD, familial Danish dementia; GSS, Gerstmann-
Sträussler-Scheinker disease; MSTD, multiple system tauopathy with presenile dementia.
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